Unity Biotechnology's Q3 2024 financial results show a reduced net loss of $6.5 million, compared to $14.8 million in Q3 2023, driven by strategic restructuring.

INmune Bio is advancing clinical trials for Alzheimer's disease (AD) and metastatic castrate-resistant prostate cancer (mCRPC), with promising early data for XPro in AD.

ANI Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Estradiol Gel, 0.06%, a generic version of EstroGel.

Shuttle Pharmaceuticals Holdings, Inc. has priced an underwritten public offering of 19,166,667 shares at $0.30 per share, expecting to raise approximately $5.75 million in gross proceeds.

The FDA has approved Protega Pharmaceuticals' ROXYBOND™ (oxycodone hydrochloride) immediate-release 10 mg tablet, featuring SentryBond™ abuse-deterrent technology, for managing severe pain.

A recent study reveals that lasofoxifene, an anti-estrogen therapy, enhances immunotherapy efficacy by promoting antitumor activity of eosinophils.

Eton Pharmaceuticals has acquired U.S. rights to Amglidia (glyburide oral suspension) from AMMTeK for treating neonatal diabetes mellitus.

Orphagen Pharmaceuticals secured a $2 million SBIR Phase II grant from the National Cancer Institute to advance OR-449, a first-in-class drug for adrenocortical carcinoma (ACC).

A Phase 3 trial of setmelanotide in children aged 2-5 with BBS, POMC, PCSK1, or LEPR deficiency demonstrated clinically meaningful reductions in BMI Z-score.

BlueRock Therapeutics, a Bayer subsidiary, is advancing its cell therapy for Parkinson's disease directly to a Phase 3 trial, aiming to provide a novel treatment option.

The FDA has accepted Rhythm Pharmaceuticals' sNDA for setmelanotide, seeking approval for children aged 2-6 with obesity due to Bardet-Biedl syndrome or POMC/LEPR deficiency.

Corvus Pharmaceuticals' ciforadenant, an adenosine A2A receptor antagonist, demonstrates potential in overcoming resistance to anti-PD1 immunotherapy in metastatic castration-resistant prostate cancer (mCRPC).

Arrowhead Pharmaceuticals has initiated the "We'll Get There Soon" campaign to raise awareness for Familial Chylomicronemia Syndrome (FCS), a rare and potentially life-threatening disease.

A recent study indicates that Osteogenon significantly reduces the time to bone union in patients with lower leg fractures treated with the Ilizarov method.

Petros Pharmaceuticals completed a Formative Human Factors study for its AI-integrated Web App, aimed at facilitating over-the-counter access to Stendra (avanafil) for erectile dysfunction.

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Lexicon's Zynquista (sotagliflozin) on October 31, 2024.

Crinetics Pharmaceuticals has announced positive Phase 2 trial results for atumelnant in treating congenital adrenal hyperplasia, participation in the 43rd Annual J.P. Morgan Healthcare Conference, and the appointment of Isabel Kalofonos as Chief Commercial Officer. Additionally, the company has granted stock options to new employees under Nasdaq Listing Rule 5635(c)(4).

Veru Inc. has commenced its Phase 2b QUALITY trial, evaluating enobosarm combined with semaglutide for sarcopenic obesity, with 168 patients enrolled.

Viking Therapeutics' stock surged following positive Phase 1 trial results for VK2735, a potential treatment for metabolic disorders.